CSL Bulls Don't See Large Impact from U.S. Pricing Deals

Dow Jones09-02 10:29

0229 GMT - CSL's bulls at UBS don't think the Australia-based pharmaceutical company will experience much of a direct financial impact from its U.S. pricing agreements. CSL has agreed to give Medicaid access to medicines at prices comparable to those in other developed economies, but the investment bank's analysts point out that the state-based program accounts for a relatively small part of its U.S. sales. On top of that, they don't see obligations around the pricing of future drug launches as onerous, given that CSL will be in control of settings and able to manage the impact in its best interests. UBS has a last-published buy rating on the stock and a target price of 181.00 Australian dollars. Shares are up 0.5% at A$173.12.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment